Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer

Xianglin L. Du, Charles R. Key, Cynthia Osborne, Jonathan D. Mahnken, James Goodwin

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Background: Although the efficacy of adjuvant chemotherapy in prolonging survival for women with breast cancer has been well documented, limited population-based information is available on the actual use of chemotherapy. Objective: To examine the relationship between age and chemotherapy use. Design: Cohort study. Setting: New Mexico. Patients: 5101 women 20 years of age of older receiving a diagnosis of stage I, stage II, or stage IIIA breast cancer from 1991 through 1997. Measurements: Pattern of chemotherapy use by age; logistic regression analysis to generate the odds and probabilities of receiving chemotherapy; and sensitivity analysis to estimate potential effects of unmeasured confounders. Results: Overall, 29% of women received chemotherapy. The rate of chemotherapy use for women with stage I, stage II, or stage IIIA breast cancer was 11%, 47%, and 68%, respectively. Across all tumor stages, the use of chemotherapy decreased substantially with increasing age (P < 0.001). Overall, 66% of women younger than 45 years of age received chemotherapy compared with 44% of women between 50 and 54 years of age, 31% of women between 55 and 59 years of age, and 18% of women between 60 and 64 years of age. The decreasing pattern of chemotherapy use with age continued after adjustment for prognostic factors and was relatively insensitive to changes in unmeasured factors. Conclusions: There is considerable discrepancy between the 1990 National Institutes of Health Consensus Conference recommendations for chemotherapy administration in women with breast cancer and the actual use of chemotherapy in the community. The decrease in use with age may relate to the decreasing efficacy of chemotherapy with age, as reported in clinical trials. Outcomes studies should address whether the recommendations are overly aggressive or whether practicing oncologists are too conservative in their use of chemotherapy.

Original languageEnglish (US)
Pages (from-to)90-97
Number of pages8
JournalAnnals of Internal Medicine
Volume138
Issue number2
StatePublished - Jan 21 2003

Fingerprint

Adjuvant Chemotherapy
Breast Neoplasms
Drug Therapy
National Institutes of Health (U.S.)
Cohort Studies
Logistic Models
Regression Analysis
Outcome Assessment (Health Care)
Clinical Trials

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. / Du, Xianglin L.; Key, Charles R.; Osborne, Cynthia; Mahnken, Jonathan D.; Goodwin, James.

In: Annals of Internal Medicine, Vol. 138, No. 2, 21.01.2003, p. 90-97.

Research output: Contribution to journalArticle

Du, Xianglin L. ; Key, Charles R. ; Osborne, Cynthia ; Mahnken, Jonathan D. ; Goodwin, James. / Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. In: Annals of Internal Medicine. 2003 ; Vol. 138, No. 2. pp. 90-97.
@article{537a684ff0b24c20be28ca9d3c3add58,
title = "Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer",
abstract = "Background: Although the efficacy of adjuvant chemotherapy in prolonging survival for women with breast cancer has been well documented, limited population-based information is available on the actual use of chemotherapy. Objective: To examine the relationship between age and chemotherapy use. Design: Cohort study. Setting: New Mexico. Patients: 5101 women 20 years of age of older receiving a diagnosis of stage I, stage II, or stage IIIA breast cancer from 1991 through 1997. Measurements: Pattern of chemotherapy use by age; logistic regression analysis to generate the odds and probabilities of receiving chemotherapy; and sensitivity analysis to estimate potential effects of unmeasured confounders. Results: Overall, 29{\%} of women received chemotherapy. The rate of chemotherapy use for women with stage I, stage II, or stage IIIA breast cancer was 11{\%}, 47{\%}, and 68{\%}, respectively. Across all tumor stages, the use of chemotherapy decreased substantially with increasing age (P < 0.001). Overall, 66{\%} of women younger than 45 years of age received chemotherapy compared with 44{\%} of women between 50 and 54 years of age, 31{\%} of women between 55 and 59 years of age, and 18{\%} of women between 60 and 64 years of age. The decreasing pattern of chemotherapy use with age continued after adjustment for prognostic factors and was relatively insensitive to changes in unmeasured factors. Conclusions: There is considerable discrepancy between the 1990 National Institutes of Health Consensus Conference recommendations for chemotherapy administration in women with breast cancer and the actual use of chemotherapy in the community. The decrease in use with age may relate to the decreasing efficacy of chemotherapy with age, as reported in clinical trials. Outcomes studies should address whether the recommendations are overly aggressive or whether practicing oncologists are too conservative in their use of chemotherapy.",
author = "Du, {Xianglin L.} and Key, {Charles R.} and Cynthia Osborne and Mahnken, {Jonathan D.} and James Goodwin",
year = "2003",
month = "1",
day = "21",
language = "English (US)",
volume = "138",
pages = "90--97",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "2",

}

TY - JOUR

T1 - Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer

AU - Du, Xianglin L.

AU - Key, Charles R.

AU - Osborne, Cynthia

AU - Mahnken, Jonathan D.

AU - Goodwin, James

PY - 2003/1/21

Y1 - 2003/1/21

N2 - Background: Although the efficacy of adjuvant chemotherapy in prolonging survival for women with breast cancer has been well documented, limited population-based information is available on the actual use of chemotherapy. Objective: To examine the relationship between age and chemotherapy use. Design: Cohort study. Setting: New Mexico. Patients: 5101 women 20 years of age of older receiving a diagnosis of stage I, stage II, or stage IIIA breast cancer from 1991 through 1997. Measurements: Pattern of chemotherapy use by age; logistic regression analysis to generate the odds and probabilities of receiving chemotherapy; and sensitivity analysis to estimate potential effects of unmeasured confounders. Results: Overall, 29% of women received chemotherapy. The rate of chemotherapy use for women with stage I, stage II, or stage IIIA breast cancer was 11%, 47%, and 68%, respectively. Across all tumor stages, the use of chemotherapy decreased substantially with increasing age (P < 0.001). Overall, 66% of women younger than 45 years of age received chemotherapy compared with 44% of women between 50 and 54 years of age, 31% of women between 55 and 59 years of age, and 18% of women between 60 and 64 years of age. The decreasing pattern of chemotherapy use with age continued after adjustment for prognostic factors and was relatively insensitive to changes in unmeasured factors. Conclusions: There is considerable discrepancy between the 1990 National Institutes of Health Consensus Conference recommendations for chemotherapy administration in women with breast cancer and the actual use of chemotherapy in the community. The decrease in use with age may relate to the decreasing efficacy of chemotherapy with age, as reported in clinical trials. Outcomes studies should address whether the recommendations are overly aggressive or whether practicing oncologists are too conservative in their use of chemotherapy.

AB - Background: Although the efficacy of adjuvant chemotherapy in prolonging survival for women with breast cancer has been well documented, limited population-based information is available on the actual use of chemotherapy. Objective: To examine the relationship between age and chemotherapy use. Design: Cohort study. Setting: New Mexico. Patients: 5101 women 20 years of age of older receiving a diagnosis of stage I, stage II, or stage IIIA breast cancer from 1991 through 1997. Measurements: Pattern of chemotherapy use by age; logistic regression analysis to generate the odds and probabilities of receiving chemotherapy; and sensitivity analysis to estimate potential effects of unmeasured confounders. Results: Overall, 29% of women received chemotherapy. The rate of chemotherapy use for women with stage I, stage II, or stage IIIA breast cancer was 11%, 47%, and 68%, respectively. Across all tumor stages, the use of chemotherapy decreased substantially with increasing age (P < 0.001). Overall, 66% of women younger than 45 years of age received chemotherapy compared with 44% of women between 50 and 54 years of age, 31% of women between 55 and 59 years of age, and 18% of women between 60 and 64 years of age. The decreasing pattern of chemotherapy use with age continued after adjustment for prognostic factors and was relatively insensitive to changes in unmeasured factors. Conclusions: There is considerable discrepancy between the 1990 National Institutes of Health Consensus Conference recommendations for chemotherapy administration in women with breast cancer and the actual use of chemotherapy in the community. The decrease in use with age may relate to the decreasing efficacy of chemotherapy with age, as reported in clinical trials. Outcomes studies should address whether the recommendations are overly aggressive or whether practicing oncologists are too conservative in their use of chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0037458216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037458216&partnerID=8YFLogxK

M3 - Article

VL - 138

SP - 90

EP - 97

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 2

ER -